Randomized placebo-controlled phase II trial of perifosine, plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4394-4400

  Bendell, Johanna C ^a   Nemunaitis, John ^b   Vukelja, Sasha J ^c   Hagenstad, Christopher ^e   Campos, Luis T ^d   Hermann, Robert C ^f   Sportelli, Peter ^g   Gardner, Lesa ^g   Richards, Donald A ^c  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c TEXAS ONCOLOGY   (United States)

^d Oncology Consultants   (United States)

^e Suburban Hematology/Oncology   (United States)

^f Northwest Georgia Oncology Centers   (United States)

^g AKEBIA THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PERIFOSINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART FAILURE; HUMAN; HYPERKALEMIA; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVARY METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; STOMACH PAIN; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHORYLCHOLINE;

EID: 81755172138     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1980     Document Type: Article

References (48)

1. Fuchs CS, Marshall J, Mitchell E, et al.: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 25:4779-4786, 2007 (Pubitemid 350086481)
2. Grothey A, Sargent D, Goldberg RM, et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004 (Pubitemid 41079833)
3. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441-9442, 2005
4. Grothey A, Sugrue MM, Purdie DM, et al.: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008
5. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007 (Pubitemid 46797944)
6. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007 (Pubitemid 350106711)
7. Brugge J, Hung MC, Mills GB: A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104-107, 2007 (Pubitemid 47199129)
8. Rychahou PG, Kang J, Gulhati P, et al.: Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 105:20315-20320, 2008
9. Sawai H, Yasuda A, Ochi N, et al.: Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 8:56, 2008
10. Baldus SE, Schaefer KL, Engers R, et al.: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790-799, 2010
11. Jehan Z, Bavi P, Sultana M, et al.: Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 219:337-346, 2009
12. Parsons DW, Wang TL, Samuels Y, et al.: Colorectal cancer: Mutations in a signalling pathway. Nature 436:792, 2005 (Pubitemid 41160630)
13. Samuels Y, Wang Z, Bardelli A, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004 (Pubitemid 38541907)
14. LoPiccolo J, Blumenthal GM, Bernstein WB, et al.: Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat 11:32-50, 2008
15. Kondapaka SB, Singh SS, Dasmahapatra GP, et al.: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093-1103, 2003
16. Chiarini F, Del Sole M, Mongiorgi S, et al.: The novel Akt inhibitor, perifosine, induces caspasedependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22:1106-1116, 2008 (Pubitemid 351833776)
17. De Siervi A, Marinissen M, Diggs J, et al.: Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: Role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1. Cancer Res 64:743-750, 2004 (Pubitemid 38120918)
18. Elrod HA, Lin YD, Yue P, et al.: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6:2029-2038, 2007 (Pubitemid 47052493)
19. Hideshima T, Catley L, Yasui H, et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062, 2006 (Pubitemid 43726814)
20. Hilgard P, Klenner T, Stekar J, et al.: D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33:442-446, 1997 (Pubitemid 27168072)
21. Li Z, Tan F, Liewehr DJ, et al.: In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst 102: 758-770, 2010
22. Momota H, Nerio E, Holland EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65:7429-7435, 2005 (Pubitemid 41161277)
23. Nyåkern M, Cappellini A, Mantovani I, et al.: Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fasmediated extrinsic cell death pathways. Mol Cancer Ther 5:1559-1570, 2006 (Pubitemid 44070493)
24. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/en/ 30publications/10policies/b3/17c.pdf
25. National Cancer Institute: National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0.9. August 2006. http://ctep.cancer.gov/protocol Development/electronic- applications/docs/ctcaev3.pdf# search="CTCAE%20version%203
26. Reference deleted
27. Bailey HH, Mahoney MR, Ettinger DS, et al.: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 107:2462-2467, 2006 (Pubitemid 44748530)
28. Unger C, Berdel W, Hanauske AR, et al.: First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 46:920-925, 2010
29. Greco FA, Infante JR, Burris HA, et al.: Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 28, 2010 (suppl; abstr e14086)
30. LoPiccolo J, Granville CA, Gills JJ, et al.: Targeting Akt in cancer therapy. Anticancer Drugs 18: 861-874, 2007 (Pubitemid 47220704)
31. Lawlor MA, Alessi DR: PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114:2903-2910, 2001 (Pubitemid 32821530)
32. Hennessy BT, Lu Y, Poradosu E, et al.: Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13:7421-7431, 2007
33. Ruiter GA, Zerp SF, Bartelink H, et al.: Anti-cancer alkyl- lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14:167-173, 2003 (Pubitemid 36269756)
34. Li X, Luwor R, Lu Y, et al.: Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTENdeficient cancer cells. Oncogene 25:525-535, 2006 (Pubitemid 43164463)
35. Krilleke D, Ucur E, Pulte D, et al.: Inhibition of JNK signaling diminishes early but not late cellular stress-induced apoptosis. Int J Cancer 107:520-527, 2003 (Pubitemid 37296110)
36. Baud V, Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40, 2009
37. Leleu X, Eeckhoute J, Jia X, et al.: Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 111:5068-5077, 2008
38. Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309, 2005 (Pubitemid 40488635)
39. Poradosu E, Lemmon M, Keleti D: Perifosine selectively inhibits binding of Akt PH domain to PtdIns(3,4)P2. 98th AACR Annual Meeting, 2007 (abstr 1645)
40. Li F, Sethi G: Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805:167-180, 2010
41. Lin Y, Bai L, Chen W, et al.: The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14:45-55, 2010
42. Voboril R, Hochwald SN, Li J, et al.: Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 120:178-188, 2004 (Pubitemid 38834184)
43. Kunnumakkara AB, Diagaradjane P, Anand P, et al.: Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125:2187-2197, 2009
44. Chen YY, Wang ZX, Chang PA, et al.: Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci 100:1708-1713, 2009
45. Lee JJ, Kim TM, Yu SJ, et al.: Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol 34:400-404, 2004 (Pubitemid 43115303)
46. Ardavanis AS, Ioannidis GN, Orphanos GS, et al.: Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res 26:1669-1672, 2006
47. Hoff PM, Pazdur R, Lassere Y, et al.: Phase II study of capecitabine in patients with fluorouracilresistant metastatic colorectal carcinoma. J Clin Oncol 22:2078-2083, 2004 (Pubitemid 41095140)
48. Gubanski M, Naucler G, Almerud A, et al.: Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 44:236-239, 2005 (Pubitemid 40904126)